KTC
ATRS

Kistler-Tiffany Companies’s Antares Pharma, Inc. ATRS Stock Holding History

Kistler-Tiffany Companies’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,000
Closed -$13K – 706
2014
Q2 		$13K Buy
+5,000
New +$15K 0.01% 407

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Kistler-Tiffany Companies's ATRS Position: Q3 2014 in Review

Kistler-Tiffany Companies sold out of Antares Pharma, Inc. (ATRS) in Q3 2014, closing a stake of 5,000 shares — an estimated $13K sold.

Kistler-Tiffany Companies first reported a position in ATRS in Q2 2014 and held it in 1 quarter. The position peaked at $13K in Q2 2014. 82 funds tracked by Wall St. Rank hold ATRS as of Q3 2014.

  • Kistler-Tiffany Companies reported no remaining Antares Pharma, Inc. position as of Q3 2014 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 5,000 Antares Pharma, Inc. shares in Q3 2014, an estimated $13K.
  • Kistler-Tiffany Companies first reported a position in Antares Pharma, Inc. in Q2 2014 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Antares Pharma, Inc. position peaked at $13K in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2014.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2014, filed 9 Oct 2014.